Frontotemporal lobe dementia (FTD) is a progressive degenerative disorder characterised by degeneration and atrophy of the frontal and anterior temporal lobes. It is the second most common neurodegenerative disorder resulting in dementia in the under 65's and a limited life expectancy. This report provides the current prevalent population for FTD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides a breakdown of the sub-group classifications of the disease, disease origin and tau protein mutations in the FTD patient population. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of FTD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for FTD include:

  • Dementia and cognitive disorders
  • Speech and semantic problems
  • Limb/muscle weakness and rigidity
  • Behavioural disorders
  • Appetite changes

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global FTD market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of FTD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on FTD prevalent population.
  • Examination of the prevalence for different causative protein mutations in FTD.
  • Identify sub-populations within FTD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of FTD patients.